Creative Planning
ADAP

Creative Planning’s Adaptimmune Therapeutics ADAP Stock Holding History

Creative Planning’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,878
Closed -$14K – 2491
2022
Q3 		$14K Buy
+12,878
New +$23.7K ﹤0.01% 2203
2019
Q3 		– Sell
-101,698
Closed -$409K – 1988
2019
Q2 		$409K Hold
101,698
– – ﹤0.01% 1184
2019
Q1 		$437K Sell
101,698
-20,000
-16% -$93.1K ﹤0.01% 1111
2018
Q4 		$700K Buy
121,698
+798
+0.7% +$5.89K ﹤0.01% 810
2018
Q3 		$1.64M Buy
120,900
+18,000
+17% +$189K 0.01% 539
2018
Q2 		$1.22M Buy
102,900
+4,000
+4% +$49.9K ﹤0.01% 642
2018
Q1 		$1.11M Buy
98,900
+32,219
+48% +$282K ﹤0.01% 679
2017
Q4 		$445K Buy
66,681
+26,681
+67% +$206K ﹤0.01% 1147
2017
Q3 		$328K Sell
40,000
-500
-1% -$3.12K ﹤0.01% 1275
2017
Q2 		$182K Hold
40,500
– – ﹤0.01% 1573
2017
Q1 		$223K Buy
40,500
+10,000
+33% +$43.7K ﹤0.01% 1421
2016
Q4 		$124K Buy
30,500
+1,000
+3% +$4.8K ﹤0.01% 1712
2016
Q3 		$208K Hold
29,500
– – ﹤0.01% 1381
2016
Q2 		$240K Sell
29,500
-3,000
-9% -$28.3K ﹤0.01% 1166
2016
Q1 		$264K Buy
32,500
+9,950
+44% +$81.4K ﹤0.01% 1074
2015
Q4 		$272K Buy
22,550
+12,050
+115% +$118K ﹤0.01% 1043
2015
Q3 		$126K Buy
+10,500
New +$148K ﹤0.01% 1454

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Creative Planning's ADAP Position: Q4 2022 in Review

Creative Planning sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 12,878 shares — an estimated $14K sold.

Creative Planning first reported a position in ADAP in Q3 2015 and held it in 17 quarters. The position peaked at $1.64M in Q3 2018. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

  • Creative Planning reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Creative Planning sold 12,878 Adaptimmune Therapeutics shares in Q4 2022, an estimated $14K.
  • Creative Planning first reported a position in Adaptimmune Therapeutics in Q3 2015 and held it in 17 quarters.
  • Creative Planning's Adaptimmune Therapeutics position peaked at $1.64M in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on Creative Planning's 13F filing for Q4 2022, filed 10 Feb 2023.